Related Experiment Video
Updated: Oct 18, 2026
A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
Published on: March 17, 2018
Selective inhibition of human lung cancer cell growth by peptides derived from retinoblastoma protein
1Molecular Concepts Research, Guardinistrasse 47, Munich, D-81375, Germany.
Abstract:
Peptides containing retinoblastoma protein (RB) fragment 649-654 (LFYKKV) were tested for their ability to block the proliferation of RB-negative and RB-positive human non-small cell lung cancer (NSCLC) cells. These peptides potently restrained the growth of both types of tumor cells, as measured by metabolic (MTT) and cellular viability (trypan blue exclusion) assays. As such, and remarkably, the peptides were able to overcome the resistance of RB-positive cells usually observed with RB gene or protein replacement therapy. Compared to the overall performance of conventional chemotherapy tested in parallel, the peptides were more cytotoxic against RB-negative neoplastic cells and equipotent toward RB-positive tumor cells, yet less toxic toward normal human cells. Thus, these new molecules hold great promise to evolve into an efficient therapy for human lung cancer, a common malignancy still defying treatment and holding a poor prognosis, as well as for other human neoplasias.
Insights
New peptides targeting retinoblastoma protein (RB) fragment 649-654 effectively inhibit non-small cell lung cancer (NSCLC) cell growth. These RB-targeting peptides show promise as a less toxic, more effective lung cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Retinoblastoma protein (RB) plays a crucial role in cell cycle regulation.
- Dysregulation of RB is implicated in various cancers, including non-small cell lung cancer (NSCLC).
- Current therapies for NSCLC, especially RB-positive cases, face challenges with resistance and toxicity.
Purpose of the Study:
- To evaluate the anti-proliferative effects of peptides containing the retinoblastoma protein (RB) fragment 649-654 (LFYKKV).
- To assess the efficacy of these peptides in both RB-negative and RB-positive human NSCLC cells.
- To compare the therapeutic potential of these peptides against conventional chemotherapy.
Main Methods:
- Synthesis and application of RB fragment 649-654 peptides.
- Cell proliferation assays including MTT and trypan blue exclusion.
- Comparative analysis with conventional chemotherapy agents on cancer and normal cells.
Main Results:
- Peptides containing RB fragment 649-654 potently inhibited the proliferation of both RB-negative and RB-positive NSCLC cells.
- The peptides demonstrated efficacy in overcoming resistance in RB-positive cells, a challenge for RB replacement therapies.
- Compared to chemotherapy, peptides were more cytotoxic to RB-negative cells, equipotent to RB-positive cells, and less toxic to normal human cells.
Conclusions:
- RB fragment 649-654 peptides represent a promising novel therapeutic strategy for human lung cancer.
- These peptides offer a potentially more effective and less toxic alternative to conventional chemotherapy for NSCLC.
- The findings suggest broader applicability of these peptides in treating other human neoplasias.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...